TNFRSF1B and acute myeloid leukemia: In AML patients subjected to epigenetic therapy, a reduction of TNFR2+ Tregs have been observed in the bone marrow of responders compared to non-responders whereas there was no difference in TNFR2− Tregs before and after treatment (101).